GLSI - Greenwich Lifesciences shares surge after late-stage breast cancer study update

Greenwich LifeSciences (GLSI) shares jump nearly 15% premarket after the company provides update on late-stage breast cancer treatment GP2 at the 2021 American Association for Cancer Research ((AACR)) Annual Meeting.The company plans to complete manufacturing of GP2 by the end of the third quarter 2021 and plans to commence the Phase III trial thereafter.The Phase III trial aims to reproduce the Phase IIb study and will explore the use of GP2 + GM-CSF as adjuvant therapy to prevent the recurrence of breast cancer in HER2/neu positive and HLA 2+ patients, post-surgery and following the first year treatment with any trastuzumab-based therapy.Greenwich LifeSciences also said that a third open-label arm has been added to the late-stage trial to test GP2 in HLA types other than HLA-A02 and to assess immune response and clinical outcome.The participant duration of the trial will be 3 years treatment plus 2 years follow-up for a total of 5 years following the

For further details see:

Greenwich Lifesciences shares surge after late-stage breast cancer study update